Thermo Fisher Q4 Earnings and Revenues Top Estimates, Stock Up

Zacks01-31

Thermo Fisher Scientific Inc.'s TMO fourth-quarter 2024 adjusted earnings per share (EPS) of $6.10 beat the Zacks Consensus Estimate by 2.9%. The figure increased 7.6% year over year. Find the latest ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2507067945?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-01-31 00:28","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2507067945","market":"us","top_or_hot":-1,"title":"Thermo Fisher Q4 Earnings and Revenues Top Estimates, Stock Up","media":"Zacks","content":"<div>\n<p>Thermo Fisher Scientific Inc.'s TMO fourth-quarter 2024 adjusted earnings per share (EPS) of $6.10 beat the Zacks Consensus Estimate by 2.9%. The figure increased 7.6% year over year.\nFind the latest ...</p>\n\n<a href=\"https://finance.yahoo.com/news/thermo-fisher-q4-earnings-revenues-162800679.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Thermo Fisher Q4 Earnings and Revenues Top Estimates, Stock Up</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThermo Fisher Q4 Earnings and Revenues Top Estimates, Stock Up\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-01-31 00:28 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/thermo-fisher-q4-earnings-revenues-162800679.html><strong>Zacks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Thermo Fisher Scientific Inc.'s TMO fourth-quarter 2024 adjusted earnings per share (EPS) of $6.10 beat the Zacks Consensus Estimate by 2.9%. The figure increased 7.6% year over year.\nFind the latest ...</p>\n\n<a href=\"https://finance.yahoo.com/news/thermo-fisher-q4-earnings-revenues-162800679.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HAE","symbol_name":"美国血液技术","start_time":0,"source_url":"https://finance.yahoo.com/news/thermo-fisher-q4-earnings-revenues-162800679.html","article_id":"2507067945","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2507067945","pubTimestamp":1738254480,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Thermo Fisher Scientific Inc.'s TMO fourth-quarter 2024 adjusted earnings per share  of $6.10 beat the Zacks Consensus Estimate by 2.9%. The figure increased 7.6% year over year.Find the latest EPS estimates and surprises on Zacks Earnings Calendar.The adjusted number excludes certain expenses, including asset amortization costs and certain restructuring costs.GAAP EPS was $4.78, up 13.8% on a year-over-year basis.Full-year adjusted EPS was $21.86, reflecting a 1.4% increase from the 2023 figure. The figure surpassed the Zacks Consensus Estimate by 0.8%.Following the earnings announcement, shares of TMO rose a modest 1.2% in pre-market trading today.Revenues in the quarter increased 4.6% year over year to $11.39 billion. Meanwhile, the top line surpassed the Zacks Consensus Estimate by 1.2%.Full-year revenues totaled $42.88 billion, up 0.05% from the 2023 level. The figure surpassed the Zacks Consensus Estimate by 0.3%.Revenues in this segment  rose 7.3% to $2.19 billion. The figure ca","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"HAE":"美国血液技术","TMO":"赛默飞世尔"},"translate_title":"赛默飞世尔第四季度盈利和收入最高预期，库存增加","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HAE":0.9,"TMO":0.9},"content_text":"Thermo Fisher Scientific Inc.'s TMO fourth-quarter 2024 adjusted earnings per share (EPS) of $6.10 beat the Zacks Consensus Estimate by 2.9%. The figure increased 7.6% year over year.\nFind the latest EPS estimates and surprises on Zacks Earnings Calendar.\nThe adjusted number excludes certain expenses, including asset amortization costs and certain restructuring costs.\nGAAP EPS was $4.78, up 13.8% on a year-over-year basis.\nFull-year adjusted EPS was $21.86, reflecting a 1.4% increase from the 2023 figure. The figure surpassed the Zacks Consensus Estimate by 0.8%.\nFollowing the earnings announcement, shares of TMO rose a modest 1.2% in pre-market trading today.\nTMO’s Q4 Revenues in Detail\nRevenues in the quarter increased 4.6% year over year to $11.39 billion. Meanwhile, the top line surpassed the Zacks Consensus Estimate by 1.2%.\nOrganic and core organic revenues in the reported quarter increased 4% and 5%, respectively.\nFull-year revenues totaled $42.88 billion, up 0.05% from the 2023 level. The figure surpassed the Zacks Consensus Estimate by 0.3%.\nThermo Fisher’s Segmental Analysis\nThermo Fisher operates under four business segments, as discussed below:\nLife Sciences Solutions\nRevenues in the Life Sciences Solutions segment (22.9% of total revenues) increased 5.3% year over year to $2.60 billion. This missed our model’s projection of $2.65 billion for this segment.\nAnalytical Instruments\nRevenues in this segment (19.2%) rose 7.3% to $2.19 billion. The figure came in line with our model’s projection.\nSpecialty Diagnostics\nRevenues in the Specialty Diagnostics segment (10.2%) increased 5.4% year over year to $1.16 billion. This surpassed our model’s projected $1.13 billion in revenues for this segment.\nLaboratory Products and Biopharma Services\nRevenues in this segment (52.1%) rose 3.8% to $5.94 billion. Our model’s projection was $5.72 billion.\nTMO’s Margin Performance\nGross margin of 43% in the fourth quarter expanded 173 basis points (bps) year over year, despite a 1.6% increase in the cost of revenues.\nIn the quarter, selling, general and administrative expenses rose 10.4% to $1.85 billion. Research and development expenses increased 14.4% to $374 million.\nThe adjusted operating margin in the quarter was 23.5%, reflecting an expansion of 61 bps.\nThermo Fisher Scientific Inc. Price, Consensus and EPS Surprise\n\n\nThermo Fisher Scientific Inc. price-consensus-eps-surprise-chart | Thermo Fisher Scientific Inc. Quote\n\nTMO’s Financial Position\nThe company ended the fourth quarter of 2024 with cash and cash equivalents and short-term investments of $5.56 billion compared with $8.08 billion at the end of the fourth quarter of 2023.\nCumulative net cash from operating activities at the end of 2024 was $3.29 billion compared with $3.72 billion a year ago.\nThermo Fisher has a consistent dividend-paying history, with the five-year annualized dividend growth being 14.89%.\nOur Take on Thermo Fisher Stock\nThermo Fisher exited the fourth quarter of 2024 with better-than-expected results, wherein both earnings and revenues beat the respective estimates. Also, all the business segments reported growth during the quarter. Expansion of both margins in the quarter was encouraging as well. The company will provide its 2025 guidance on the earnings call today.\nDuring 2024, the company advanced in its growth strategy by launching a range of high-impact, innovative new products, which include the Thermo Scientific Iliad (Scanning) Transmission Electron Microscope, the Thermo Scientific Stellar mass spectrometer, the Thermo Scientific Dionex Inuvion Ion Chromatography system, the Applied Biosystems MagMAX Sequential DNA/RNA kit, the Thermo Scientific iCAP MX Series ICP-MS and new additions to the Gibco CTS Detachable Dynabeads platform. Additionally, in 2024, Thermo Fisher completed the acquisition of Olink, a leading provider of advanced solutions for proteomics research. All these developments translated into meaningful commercial wins for the company in 2024, which is encouraging.\nTMO’s Zacks Rank and Key Picks\nThermo Fisher currently carries a Zacks Rank #4 (Sell).\nSome better-ranked stocks from the broader medical space are Veracyte VCYT, Cardinal Health CAH and Haemonetics HAE.\nVeracyte, sporting a Zacks Rank #1 (Strong Buy) at present, reported third-quarter 2024 adjusted EPS of 19 cents, which surpassed the Zacks Consensus Estimate by a huge 850%. Revenues of $115.9 million topped the Zacks Consensus Estimate by 5.8%. You can see the complete list of today’s Zacks #1 Rank stocks here.\nVCYT has an estimated earnings growth rate of 137.2% for 2024 compared with the industry’s 15%. The company’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 520.58%.\nCardinal Health, carrying a Zacks Rank #2 (Buy) at present, posted first-quarter fiscal 2025 adjusted EPS of $1.88, which exceeded the Zacks Consensus Estimate by 9.8%. Revenues of $52.28 billion surpassed the Zacks Consensus Estimate by 2%. CAH has an estimated long-term earnings growth rate of 10.5% compared with the industry’s 9.6%. The company’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 11.24%.\nHaemonetics, carrying a Zacks Rank #2 at present, reported second-quarter fiscal 2025 adjusted EPS of $1.12, which surpassed the Zacks Consensus Estimate by 2.8%. Revenues of $345.5 million topped the Zacks Consensus Estimate by 0.7%. HAE has an estimated earnings growth rate of 15.9% for fiscal 2025 compared with the industry’s 12.2%. The company’s earnings surpassed estimates in three of the trailing four quarters and missed in one, the average surprise being 2.82%.\nWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report\nThermo Fisher Scientific Inc. (TMO) : Free Stock Analysis Report\nCardinal Health, Inc. (CAH) : Free Stock Analysis Report\nHaemonetics Corporation (HAE) : Free Stock Analysis Report\nVeracyte, Inc. (VCYT) : Free Stock Analysis Report\nTo read this article on Zacks.com click here.\nZacks Investment Research","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.30.2","shortVersion":"4.30.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2507067945"}